JP2007507222A - 化学療法に対する応答を予測するための遺伝子発現マーカー - Google Patents

化学療法に対する応答を予測するための遺伝子発現マーカー Download PDF

Info

Publication number
JP2007507222A
JP2007507222A JP2006533426A JP2006533426A JP2007507222A JP 2007507222 A JP2007507222 A JP 2007507222A JP 2006533426 A JP2006533426 A JP 2006533426A JP 2006533426 A JP2006533426 A JP 2006533426A JP 2007507222 A JP2007507222 A JP 2007507222A
Authority
JP
Japan
Prior art keywords
expression
cancer
array
chemotherapy
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507222A5 (enExample
Inventor
ジョフリ ビー． ベーカー，
キャシー ディー． ミラー，
スティーブン シャク，
ジョージ ダブリュー． スレッジ，
シャロン イー． スーレ，
Original Assignee
ゲノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲノミック ヘルス， インコーポレイテッド filed Critical ゲノミック ヘルス， インコーポレイテッド
Publication of JP2007507222A publication Critical patent/JP2007507222A/ja
Publication of JP2007507222A5 publication Critical patent/JP2007507222A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006533426A 2003-05-28 2004-05-24 化学療法に対する応答を予測するための遺伝子発現マーカー Pending JP2007507222A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47397003P 2003-05-28 2003-05-28
PCT/US2004/016553 WO2004111603A2 (en) 2003-05-28 2004-05-24 Gene expression markers for predicting response to chemotherapy

Publications (2)

Publication Number Publication Date
JP2007507222A true JP2007507222A (ja) 2007-03-29
JP2007507222A5 JP2007507222A5 (enExample) 2007-06-14

Family

ID=33551472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533426A Pending JP2007507222A (ja) 2003-05-28 2004-05-24 化学療法に対する応答を予測するための遺伝子発現マーカー

Country Status (6)

Country Link
US (1) US20050064455A1 (enExample)
EP (1) EP1631689A2 (enExample)
JP (1) JP2007507222A (enExample)
AU (1) AU2004248120B2 (enExample)
CA (1) CA2527285A1 (enExample)
WO (1) WO2004111603A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール
JP2016508710A (ja) * 2012-12-03 2016-03-24 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2258872T3 (da) * 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
US8691506B2 (en) 2005-04-13 2014-04-08 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
ES2404066T3 (es) * 2005-09-21 2013-05-23 Epigenomics Ag Marcadores para la predicción del resultado de un tratamiento con antraciclina
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
JP2009532035A (ja) * 2006-03-31 2009-09-10 ブリストル−マイヤーズ スクイブ カンパニー 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
TW200817680A (en) * 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20090125247A1 (en) * 2007-08-16 2009-05-14 Joffre Baker Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2065475A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
ES2482692T3 (es) * 2008-05-12 2014-08-04 Genomic Health, Inc. Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia
CA2725978A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
GB0908467D0 (en) 2009-05-15 2009-06-24 Univ Gent Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression
ES2351327B1 (es) * 2009-07-01 2011-11-28 Para La Investigacion Biomedica Del Hospital Universitario La Paz Fundacion Método de obtención de datos útiles para la predicción de respuesta clínica a un tratamiento de un paciente con cáncer.
ES2351328B1 (es) * 2009-07-10 2011-11-28 Para La Investigacion Biomedica Del Hospital Universitario La Paz Fundacion Método de obtención de datos útiles para la predicción de respuesta patológica a un tratamiento de un paciente con cáncer.
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
CA2781044A1 (en) * 2009-11-20 2011-05-26 The Governors Of The University Of Alberta Predictive markers for taxane responsiveness and methods of use thereof
CN101760557B (zh) * 2010-03-04 2013-08-14 中国人民解放军军事医学科学院放射与辐射医学研究所 一种辅助诊断肝细胞癌的试剂盒
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013049666A1 (en) 2011-09-30 2013-04-04 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
EP2785873A4 (en) * 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
HUE045880T2 (hu) * 2012-07-31 2020-01-28 Novartis Ag A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9535055B2 (en) 2013-03-28 2017-01-03 Samsung Electronics Co., Ltd. Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
EP3014505A4 (en) * 2013-06-28 2017-03-08 Nantomics, LLC Pathway analysis for identification of diagnostic tests
HK1215453A1 (zh) * 2013-07-03 2016-08-26 豪夫迈．罗氏有限公司 用於将用mdm2拮抗剂进行患者癌症治疗个人化的基於mrna的基因表达
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
KR20150088433A (ko) 2014-01-24 2015-08-03 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3230314B1 (en) 2014-12-08 2023-05-03 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016141088A1 (en) 2015-03-02 2016-09-09 Sarcotein Diagnostics, Llc 13+/17+ bin1 expression as a marker of cardiac disorders
US11092603B2 (en) * 2015-10-29 2021-08-17 The Research Foundation For The State University Of New York Keratin 17 as a prognostic marker for pancreatic cancer
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
GB201716712D0 (en) 2017-10-12 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Prognostic and treatment response predictive method
CN107808377B (zh) * 2017-10-31 2019-02-12 北京青燕祥云科技有限公司 一种肺叶中病灶的定位装置
US20220275458A1 (en) * 2019-08-07 2022-09-01 University Of Massachusetts Prediction of cancer therapy efficacy
ES3066049T3 (enExample) * 2022-12-07 2026-05-11 Oncomatryx Biopharma S L

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2001232485A1 (en) * 2000-01-13 2001-07-24 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
WO2001055454A1 (en) * 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
AU2001251086A1 (en) * 2000-03-31 2001-10-15 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
JP2004537261A (ja) * 2000-12-08 2004-12-16 イプソゲン 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング
US6939670B2 (en) * 2001-03-12 2005-09-06 Monogen, Inc. Cell-based detection and differentiation of lung cancer
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
DK2258872T3 (da) * 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010038077, 医学のあゆみ， （２００２）， ２０３， ［３］， ｐ．１８９−１９０ *
JPN6010038078, Ｎａｔ． Ｍｅｄ．， （２００１）， ７， ［２］， ｐ．１９２−１９８ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539973A (ja) * 2007-10-05 2010-12-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2015165811A (ja) * 2007-10-05 2015-09-24 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2017060517A (ja) * 2007-10-05 2017-03-30 パシフィック エッジ バイオテクノロジー リミティド 胃腸癌での増殖の徴候及び予後
JP2018126154A (ja) * 2007-10-05 2018-08-16 パシフィック エッジ リミテッド 胃腸癌での増殖の徴候及び予後
JP2012523828A (ja) * 2009-04-17 2012-10-11 ユニヴェルシテ リブル ドゥ ブリュッセル ガンにおけるアントラサイクリン系薬剤の効率を予測するための方法およびツール
JP2016508710A (ja) * 2012-12-03 2016-03-24 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価
US10460831B2 (en) 2012-12-03 2019-10-29 Koninklijke Philips N.V. Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab

Also Published As

Publication number Publication date
CA2527285A1 (en) 2004-12-23
EP1631689A2 (en) 2006-03-08
US20050064455A1 (en) 2005-03-24
AU2004248120B2 (en) 2009-04-23
WO2004111603A3 (en) 2005-07-21
AU2004248120A1 (en) 2004-12-23
WO2004111603A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
JP6190434B2 (ja) 化学療法剤に対する応答を予測するための遺伝子発現マーカー
AU2004248120B2 (en) Gene expression markers for predicting response to chemotherapy
JP4680898B2 (ja) 癌再発の可能性の予測
JP4723472B2 (ja) 乳癌予後診断のための遺伝子発現マーカー
JP5020088B2 (ja) 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
JP2007506442A (ja) Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
EP3556867A1 (en) Methods to predict clinical outcome of cancer
EP3580357A1 (en) Algorithms and methods for assessing late clinical endpoints in prostate cancer
AU2011204944B2 (en) Gene expression markers for predicting response to chemotherapy
AU2017228579B2 (en) Prediction of likelihood of cancer recurrence
AU2016210735B2 (en) Gene expression markers for predicting response to chemotherapy
KR20070022694A (ko) 화학요법 반응을 예측하기 위한 유전자 발현 마커
HK40011641B (en) Algorithms and methods for assessing late clinical endpoints in prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090501

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101201